As antibody-drug conjugates (ADCs) continue to transform cancer treatment, manufacturers face increasing pressure to deliver these highly complex therapies faster, more safely, and with greater reliability. Yet one of the industry's most persistent challenges remains the fragmented supply chain traditionally required to produce ADCs.
Submit Your Best Content to ISPE
ISPE’s official blog, iSpeak accepts contributions from our Members and professionals in the pharma industry.